The development of a novel cancer immunotherapeutic platform using tumor-targeting mesenchymal stem cells and a protein vaccine

Hon Jian Wei, Alexander Wu, Chung Huei Hsu, Yi Ping Lin, Wen Fang Cheng, Ching Hua Su, Wen Ta Chiu, Jacqueline Whang-Peng, Frank L. Douglas, Win Ping Deng

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

An ideal anticancer strategy should target only the malignant cells but spare the normal ones. In this regard, we established a platform, consisting of an antigen-delivering vehicle and a protein vaccine, for developing an immunotherapeutic approach with the potential for eliminating various cancer types. Mesenchymal stem cells (MSCs) have been demonstrated capable of targeting tumors and integrating into the stroma. Moreover, we have developed a protein vaccine PE(ΔIII)-E7-KDEL3 which specifically recognized E7 antigen and elicited immunity against cervical cancer. Taking advantage of tumor-homing property of MSCs and PE(ΔIII)-E7-KDEL3, we used E6/E7-immortalized human MSCs (KP-hMSCs) as an E7 antigen-delivering vehicle to test if this protein vaccine could effectively eliminate non-E7-expressing tumor cells. Animals which received combined treatment of KP-hMSCs and PE(ΔIII)-E7-KDEL3 demonstrated a significant inhibition of tumor growth and lung-metastasis when compared to PE(ΔIII)-E7-KDEL3 only and KP-hMSCs only groups. The efficiency of tumor suppression correlated positively to the specific immune response induced by PE(ΔIII)-E7-KDEL3. In addition, this combined treatment inhibited tumor growth via inducing apoptosis. Our findings indicated that KP-hMSCs could be used as a tumor-targeting device and mediate antitumor effect of PE(ΔIII)-E7-KDEL3. We believe this strategy could serve as a platform for developing a universal vaccine for different cancer types.

Original languageEnglish
Pages (from-to)2249-2257
Number of pages9
JournalMolecular Therapy
Volume19
Issue number12
DOIs
Publication statusPublished - Dec 2011

Fingerprint

Mesenchymal Stromal Cells
Vaccines
Neoplasms
Proteins
Antigens
Cancer Vaccines
Growth
Uterine Cervical Neoplasms
Immunity
Apoptosis
Neoplasm Metastasis
Equipment and Supplies
Lung

ASJC Scopus subject areas

  • Molecular Biology
  • Molecular Medicine
  • Genetics
  • Drug Discovery
  • Pharmacology

Cite this

The development of a novel cancer immunotherapeutic platform using tumor-targeting mesenchymal stem cells and a protein vaccine. / Wei, Hon Jian; Wu, Alexander; Hsu, Chung Huei; Lin, Yi Ping; Cheng, Wen Fang; Su, Ching Hua; Chiu, Wen Ta; Whang-Peng, Jacqueline; Douglas, Frank L.; Deng, Win Ping.

In: Molecular Therapy, Vol. 19, No. 12, 12.2011, p. 2249-2257.

Research output: Contribution to journalArticle

Wei, Hon Jian ; Wu, Alexander ; Hsu, Chung Huei ; Lin, Yi Ping ; Cheng, Wen Fang ; Su, Ching Hua ; Chiu, Wen Ta ; Whang-Peng, Jacqueline ; Douglas, Frank L. ; Deng, Win Ping. / The development of a novel cancer immunotherapeutic platform using tumor-targeting mesenchymal stem cells and a protein vaccine. In: Molecular Therapy. 2011 ; Vol. 19, No. 12. pp. 2249-2257.
@article{1435a332c6564af3aff6987f2b905ed6,
title = "The development of a novel cancer immunotherapeutic platform using tumor-targeting mesenchymal stem cells and a protein vaccine",
abstract = "An ideal anticancer strategy should target only the malignant cells but spare the normal ones. In this regard, we established a platform, consisting of an antigen-delivering vehicle and a protein vaccine, for developing an immunotherapeutic approach with the potential for eliminating various cancer types. Mesenchymal stem cells (MSCs) have been demonstrated capable of targeting tumors and integrating into the stroma. Moreover, we have developed a protein vaccine PE(ΔIII)-E7-KDEL3 which specifically recognized E7 antigen and elicited immunity against cervical cancer. Taking advantage of tumor-homing property of MSCs and PE(ΔIII)-E7-KDEL3, we used E6/E7-immortalized human MSCs (KP-hMSCs) as an E7 antigen-delivering vehicle to test if this protein vaccine could effectively eliminate non-E7-expressing tumor cells. Animals which received combined treatment of KP-hMSCs and PE(ΔIII)-E7-KDEL3 demonstrated a significant inhibition of tumor growth and lung-metastasis when compared to PE(ΔIII)-E7-KDEL3 only and KP-hMSCs only groups. The efficiency of tumor suppression correlated positively to the specific immune response induced by PE(ΔIII)-E7-KDEL3. In addition, this combined treatment inhibited tumor growth via inducing apoptosis. Our findings indicated that KP-hMSCs could be used as a tumor-targeting device and mediate antitumor effect of PE(ΔIII)-E7-KDEL3. We believe this strategy could serve as a platform for developing a universal vaccine for different cancer types.",
author = "Wei, {Hon Jian} and Alexander Wu and Hsu, {Chung Huei} and Lin, {Yi Ping} and Cheng, {Wen Fang} and Su, {Ching Hua} and Chiu, {Wen Ta} and Jacqueline Whang-Peng and Douglas, {Frank L.} and Deng, {Win Ping}",
year = "2011",
month = "12",
doi = "10.1038/mt.2011.152",
language = "English",
volume = "19",
pages = "2249--2257",
journal = "Molecular Therapy",
issn = "1525-0016",
publisher = "Nature Publishing Group",
number = "12",

}

TY - JOUR

T1 - The development of a novel cancer immunotherapeutic platform using tumor-targeting mesenchymal stem cells and a protein vaccine

AU - Wei, Hon Jian

AU - Wu, Alexander

AU - Hsu, Chung Huei

AU - Lin, Yi Ping

AU - Cheng, Wen Fang

AU - Su, Ching Hua

AU - Chiu, Wen Ta

AU - Whang-Peng, Jacqueline

AU - Douglas, Frank L.

AU - Deng, Win Ping

PY - 2011/12

Y1 - 2011/12

N2 - An ideal anticancer strategy should target only the malignant cells but spare the normal ones. In this regard, we established a platform, consisting of an antigen-delivering vehicle and a protein vaccine, for developing an immunotherapeutic approach with the potential for eliminating various cancer types. Mesenchymal stem cells (MSCs) have been demonstrated capable of targeting tumors and integrating into the stroma. Moreover, we have developed a protein vaccine PE(ΔIII)-E7-KDEL3 which specifically recognized E7 antigen and elicited immunity against cervical cancer. Taking advantage of tumor-homing property of MSCs and PE(ΔIII)-E7-KDEL3, we used E6/E7-immortalized human MSCs (KP-hMSCs) as an E7 antigen-delivering vehicle to test if this protein vaccine could effectively eliminate non-E7-expressing tumor cells. Animals which received combined treatment of KP-hMSCs and PE(ΔIII)-E7-KDEL3 demonstrated a significant inhibition of tumor growth and lung-metastasis when compared to PE(ΔIII)-E7-KDEL3 only and KP-hMSCs only groups. The efficiency of tumor suppression correlated positively to the specific immune response induced by PE(ΔIII)-E7-KDEL3. In addition, this combined treatment inhibited tumor growth via inducing apoptosis. Our findings indicated that KP-hMSCs could be used as a tumor-targeting device and mediate antitumor effect of PE(ΔIII)-E7-KDEL3. We believe this strategy could serve as a platform for developing a universal vaccine for different cancer types.

AB - An ideal anticancer strategy should target only the malignant cells but spare the normal ones. In this regard, we established a platform, consisting of an antigen-delivering vehicle and a protein vaccine, for developing an immunotherapeutic approach with the potential for eliminating various cancer types. Mesenchymal stem cells (MSCs) have been demonstrated capable of targeting tumors and integrating into the stroma. Moreover, we have developed a protein vaccine PE(ΔIII)-E7-KDEL3 which specifically recognized E7 antigen and elicited immunity against cervical cancer. Taking advantage of tumor-homing property of MSCs and PE(ΔIII)-E7-KDEL3, we used E6/E7-immortalized human MSCs (KP-hMSCs) as an E7 antigen-delivering vehicle to test if this protein vaccine could effectively eliminate non-E7-expressing tumor cells. Animals which received combined treatment of KP-hMSCs and PE(ΔIII)-E7-KDEL3 demonstrated a significant inhibition of tumor growth and lung-metastasis when compared to PE(ΔIII)-E7-KDEL3 only and KP-hMSCs only groups. The efficiency of tumor suppression correlated positively to the specific immune response induced by PE(ΔIII)-E7-KDEL3. In addition, this combined treatment inhibited tumor growth via inducing apoptosis. Our findings indicated that KP-hMSCs could be used as a tumor-targeting device and mediate antitumor effect of PE(ΔIII)-E7-KDEL3. We believe this strategy could serve as a platform for developing a universal vaccine for different cancer types.

UR - http://www.scopus.com/inward/record.url?scp=82955187782&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=82955187782&partnerID=8YFLogxK

U2 - 10.1038/mt.2011.152

DO - 10.1038/mt.2011.152

M3 - Article

VL - 19

SP - 2249

EP - 2257

JO - Molecular Therapy

JF - Molecular Therapy

SN - 1525-0016

IS - 12

ER -